探讨孟鲁司特联合布地奈德对支气管哮喘儿童氧化应激及炎症因子影响

The Investigatation on the Effect of Montelukast Combined with Budesonide on Oxidative Stress and Inflammatory Cytokines in Children with Bronchial Asthma

目的:探讨孟鲁司特联合布地奈德对支气管哮喘儿童氧化应激及炎症因子的影响。方法:以笔者所在医院2015年2月-2016年10月收治的76例支气管哮喘患儿为研究对象,将其随机分为观察组和对照组,每组38例。两组患儿均给予抗感染、平喘、吸氧等常规治疗。在此基础上对照组给予布地奈德治疗,观察组给予孟鲁司特联合布地奈德治疗。分析两组治疗前后超氧化物歧化酶(SOD)和丙二醛(MDA)及肿瘤坏死因子(TNF-α)、白介素-4(IL-4)、白介素-8(IL-8)等指标的变化情况。结果:治疗6个月后,两组患儿的SOD明显上升、MDA显著下降,与治疗前比较差异均有统计学意义(t=46.523、23.730、12.195、8.105,P<0.01);观察组的SOD和MDA显著优于对照组,差异均有统计学意义(t=18.382、3.049,P<0.01);治疗6个月后,两组患儿TNF-α、IL-4、IL-8水平均显著低于治疗前,差异均有统计学意义(t_(观察组)=10.184、26.916、8.026,t_(对照组)=7.804、13.718、21.847,P<0.05),且观察组上述指标明显低于对照组,差异均有统计学意义(t=3.644、11.741、3.343,P<0.05)。结论:支气管哮喘儿童采取孟鲁司特联合布地奈德治疗,可显著抑制患儿的氧化应激反应,并有效降低其炎症因子水平,疗效确切,值得临床推广应用。

Objective： To investigate the effect of Montelukast combined with Budesonide on oxidative stress and inflammatory factors in children with bronchial asthma.Method： A total of 76 cases of bronchial asthma in our hospital from February 2015 to October 2016 were selected as the research subjects.They were randomly divided into the observation group and the control group, 38 cases in each group.The children in both of the two groups were given conventional treatment, such as anti infection, antiasthmatic and oxygen inhalation.On this basis, the control group was treated with Budesonide, while the observation group was given Montelukast combined with budesonide.The changes of superoxide dismutase（SOD）, malondialdehyde（MDA）, tumor necrosis factor（TNF-α）, interleukin-4（IL-4） and interleukin-8（IL-8） in two groups before and after treatment were analyzed.Result： After 6 months of treatment, the SOD increased significantly and the MDA decreased significantly in both two groups, and the differences were statistically significant（t=46.523, 23.730, 12.195, 8.105, P〈0.01）, the changes of SOD and MDA in the observation group were more significant than those in the control group, the differences were statistically significant（t=18.382, 3.049, P〈0.01）.After 6 months of treatment, the levels of TNF-α, IL-4 and IL-8 in the observation group and the control group were significantly lower than those before treatment, the differences were statistically significant（t观察组=10.184, 26.916, 8.026, t对照组=7.804, 13.718, 21.847, P〈0.05）, and the indexes in the observation group were significantly lower than those in the control group, the differences were statistically significant（t=3.644, 11.741, 3.343, P〈0.05）.Conclusion： Montelukast combined with Budesonide in children with bronchial asthma can significantly inhibit oxidative stress and reduce the level of inflammatory factors, which is worthy of clinical application.